(Q48449468)

11 February 2018

title

Association between regional brain volumes and clozapine response in schizophrenia. (English)

1 reference

11 February 2018

1 reference

2

1 reference

11 February 2018

author name string

Lauriello J

1

1 reference

11 February 2018

Rosenbloom M

3

1 reference

11 February 2018

Sullivan EV

4

1 reference

11 February 2018

Faustman WO

5

1 reference

11 February 2018

Ringo DL

6

1 reference

11 February 2018

Lim KO

7

1 reference

11 February 2018

Pfefferbaum A

8

1 reference

11 February 2018

language of work or name

English

0 references

publication date

1 June 1998

1 reference

11 February 2018

published in

Biological Psychiatry

1 reference

11 February 2018

volume

43

1 reference

11 February 2018

issue

12

1 reference

11 February 2018

page(s)

879-886

1 reference

11 February 2018

Cost-effectiveness of clozapine. A UK clinic-based study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Clozapine. A novel antipsychotic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Reduction of cortical volume in schizophrenia on magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Regional cortical anatomy and clozapine response in refractory schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

The use of clozapine in treatment-refractory schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Decreased Gray Matter in Normal Aging: An in Vivo Magnetic Resonance Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Cortical gray matter volume deficits in schizophrenia: a replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Correction for head size in brain-imaging measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Auditory P300 abnormalities and left posterior superior temporal gyrus volume reduction in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Brain gray and white matter volume loss accelerates with aging in chronic alcoholics: a quantitative MRI study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Abnormalities of the left temporal lobe in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Decreased regional cortical gray matter volume in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

A profile of cortical gray matter volume deficits characteristic of schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Patterns of regional cortical dysmorphology distinguishing schizophrenia and chronic alcoholism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Prefrontal cortex and schizophrenia. A quantitative magnetic resonance imaging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

MRI brain abnormalities in chronic schizophrenia: one process or more?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Widespread cerebral gray matter volume deficits in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

Segmentation of MR brain images into cerebrospinal fluid spaces, white and gray matter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900491-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(97)00491-5

1 reference

11 February 2018

release_3ms53wz2orcexgjkq5qutxzsie

Fatcat ID

0 references

PubMed ID

9627742

1 reference

11 February 2018